TWB Business Summary

Taiwan Bio Therapeutics (TWB; 6892.TWO) is a leading Taiwanese biotechnology firm specializing in regenerative medicine through a dual-engine business model that integrates proprietary drug development with high-end Contract Development and Manufacturing Organization (CDMO) services. The company generates revenue primarily through its "Therapeutic Design & Manufacturing" (TDM) model, which provides end-to-end cell therapy production for global partners, and through the licensing of its allogeneic stem cell pipeline. Its primary business segments focus on Mesenchymal Stem Cells (MSC) and Regulatory T cells (Treg), supported by the proprietary FAST CGT platform designed to optimize cell engineering and reduce manufacturing costs. Within the regional landscape, TWB competes directly with domestic peers such as Synbio Tech (1295.TWO), Gwo Xi Stem Cell Applied Technology (6704.TWO), and TWi Biotechnology (6610.TWO), positioning itself as a specialized innovator in non-cancer inflammatory and autoimmune indications. The leadership team is anchored by Chairman Dr. Hsu-Sung Kuo, the former Director-General of the Taiwan Centers for Disease Control, and CEO Dr. Cyrus Yang (Chun-Yao Yang), who holds a PhD in translational immunology from the University of Oxford. Dr. Yang is credited with pivoting the company toward a global innovation strategy, including the 2025 acquisition of a U.S.-based Treg firm to form the Singulera Therapeutics subsidiary. The executive suite also includes Chief Financial Officer Lisa Juang, who oversees corporate governance and investor relations. Founded in 2014 by a physician-scientist from Taipei Veterans General Hospital, the company is backed by notable institutional investors including Medigen Biotechnology Corp., Schweitzer Biotech Co., and Collins Co., Ltd., reflecting strong support from Taiwan's established life sciences ecosystem.